ANI Pharmaceuticals Given Outperform Rating at Oppenheimer (ANIP)
ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “outperform” rating reaffirmed by analysts at Oppenheimer in a research report issued to clients and investors on Thursday. They currently have a $35.00 price target on the stock, down from their previous price target of $40.00. Oppenheimer’s price target would indicate a potential upside of 30.89% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $40.60 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $36.00 to $38.00 in a research note on Tuesday, May 6th.
Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 4.37% on Thursday, hitting $26.74. The stock had a trading volume of 342,160 shares. ANI Pharmaceuticals has a one year low of $5.99 and a one year high of $38.74. The stock’s 50-day moving average is $33.36 and its 200-day moving average is $30.00. The company has a market cap of $301.7 million and a price-to-earnings ratio of 184.32.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Monday, May 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 94.6% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals will post $1.17 EPS for the current fiscal year.
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.